文献速递淋巴瘤

维奈克拉联合伊布替尼治疗套细胞淋巴瘤的七年结局:持久缓解与无治疗缓解

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
PubMed 文献 · Blood · 2024-01-01

在维奈克拉-伊布替尼的2期临床试验(AIM)中,24例套细胞淋巴瘤(MCL)患者(23例为复发/难治性疾病)接受伊布替尼560 mg和维奈克拉400 mg每日一次治疗。中位幸存者随访超过7年,复发/难治MCL的7年无进展生存(PFS)估计为30%(95%CI 14-49),总生存(OS)为43%(95%CI 23-62)。8例达到MRD阴性完全缓解(CR)的患者进入选择性治疗中断(ETI),中位持续58个月(95%CI 37-79),其中4例出现疾病复发。

要点

  • 复发/难治MCL患者7年PFS估计为30%(95%CI 14-49),7年OS为43%(95%CI 23-62)。
  • 8例MRD阴性CR患者进入ETI,中位58个月(95%CI 37-79),4例复发,3例再治疗中2例再获CR。
  • 56周后≥3级不良事件和严重不良事件不常见,未观察到新发或加重的心血管毒性。

核心结论

  • 维奈克拉联合伊布替尼在复发/难治套细胞淋巴瘤中显示长期持久缓解和可接受的毒性特征,并证明治疗中断维持疾病控制的可行性。

研究设计与样本

  • 2期临床试验(AIM,NCT02471391),24例套细胞淋巴瘤患者(23例为复发/难治性疾病)接受伊布替尼560 mg和维奈克拉400 mg每日一次治疗。
  • 治疗最初为连续给药,方案修订后允许MRD阴性CR患者进行选择性治疗中断(ETI)。

主要发现

  • 复发/难治MCL的估计7年PFS为30%(95%CI 14-49;中位PFS 28个月,95%CI 13-82),7年OS为43%(95%CI 23-62;中位OS 32个月,95%CI 15至不可评估)。
  • 8例MRD阴性CR患者进入ETI,中位持续58个月(95%CI 37-79),其中4例出现疾病复发;3例再治疗患者中2例再获CR。
  • 排除ETI期间再获缓解者进展的时间-治疗失败(TTF)总体为39%,缓解者7年时为68%。
  • 56周后,≥3级不良事件和严重不良事件不常见;56周后未观察到新发或加重的心血管毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received ibrutinib 560 mg and venetoclax 400 mg both once daily. High complete remission (CR) and measurable residual disease negative (MRD-negative) CR rates were previously reported. With median survivor follow-up now exceeding 7 years, we report long-term results. Treatment was initially continuous, with elective treatment interruption (ETI) allowed after protocol amendment for patients in MRD-negative CR. For R/R MCL, the estimated 7-year progression-free survival (PFS) was 30% (95% confidence interval [CI], 14-49; median, 28 months; 95% CI, 13-82) and overall survival (OS) was 43% (95% CI, 23-62; median, 32 months; 95% CI, 15 to not evaluable). Eight patients in MRD-negative CR entered ETI for a median of 58 months (95% CI, 37-79), with 4 experiencing disease recurrence. Two of 3 reattained CR on retreatment. Time-to-treatment failure (TTF), which excluded progression in ETI for those reattaining response, was 39% overall and 68% at 7 years for responders. Beyond 56 weeks, grade ≥3 and serious adverse events were uncommon. Newly emergent or increasing cardiovascular toxicity were not observed beyond 56 weeks. We demonstrate long-term durable responses and acceptable toxicity profile of venetoclax-ibrutinib in R/R MCL and show feasibility of treatment interruption while maintaining ongoing disease control. This trial was registered at www.clinicaltrials.gov as #NCT02471391.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Handunnetti SM, Anderson MA, Burbury K, et al. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 2024. PMID: 38662991. doi:10.1182/blood.2023023388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。